MURRAY HILL, N.J.--(BUSINESS WIRE)--March 3, 2006--C. R. Bard,
Inc. (NYSE:BCR) today announced that it has concluded enrollment in
its respiratory infection control (RIC) endotracheal (ET) tube
clinical trial. Based on Data Safety Monitoring Board review and
input, the company believes that current trends in the data support
the trial's secondary endpoint, the delayed onset of ventilator
associated pneumonia (VAP). As a result, the company has decided to
conclude enrollment in the study and to pursue 510(k) concurrence from
the United States Food and Drug Administration (FDA) after trial
follow-up is completed.
The trial is a prospective, multi-center, randomized, sequential
design clinical study of the incidence and time to onset of VAP in
patients who require mechanical ventilation. VAP is one of the most
costly hospital acquired infections and has an associated mortality
rate greater than 50 percent. It is especially prevalent in hospital
intensive care units where patients are typically on an endotracheal
tube for one to 10 days. The company's endotracheal tube incorporates
its proprietary, silver-eluting technology. Subject to FDA
concurrence, the company continues to anticipate launch of the product
in the first half of 2007.
C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer, and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management's current expectations, the accuracy of
which is necessarily subject to risks and uncertainties. These
statements are not historical in nature and use words such as
"anticipate", "estimate", "expect", "project", "intend", "forecast",
"plan", "believe", and other words of similar meaning in connection
with any discussion of future operating or financial performance. Many
factors may cause actual results to differ materially from anticipated
results including product developments, sales efforts, income tax
matters, the outcomes of contingencies such as legal proceedings, and
other economic, business, competitive and regulatory factors. The
company undertakes no obligation to update its forward-looking
statements. Please refer to our December 31, 2005 10-K for more
detailed information about these and other factors that may cause
actual results to differ materially from those expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Holly P. Glass, 571-243-1952
SOURCE: C. R. Bard, Inc.